Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Salmeterol 50μg bid significantly reduces moderate-severe exacerbations in patients with all severities of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 68s Year: 2003
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
LATE-BREAKING ABSTRACT: Once-daily QVA149 significantly improves lung function and symptoms compared to twice-daily fluticasone/salmeterol in COPD patients: The ILLUMINATE study Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments Year: 2012
Financial benefits of fluticasone propionate/salmeterol 250/50 mcg fixed dose combination over tiotropium in elderly managed COPD patient Source: Annual Congress 2010 - Management of airway disease Year: 2010
Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 26s Year: 2001
LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 250s Year: 2002
Budesonide/formoterol improves exercise tolerance compared with placebo and formoterol in COPD patients Source: Annual Congress 2009 - Influence of interventions and comorbidity on exercise performance Year: 2009
Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice Source: Eur Respir J 2001; 18: Suppl. 33, 348s Year: 2001
LATE-BREAKING ABSTRACT: Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE study Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012
Once-daily QVA149 improves lung function and health status versus twice-daily salmeterol/fluticasone (SFC) in symptomatic GOLD B and GOLD D COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Improvements in FEV1 and symptoms in poorly-reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003
QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Once-daily QVA149 improves symptom scores in patients with COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013